Background/Aims Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce. Therefore, this study aimed to evaluate the effect of TAF on the lipid in patients with CHB.
Methods A total of 237 TAF-treated CHB patients compared with TDF, inactive CHB, and non-hepatitis B virus (HBV)-infected control groups using propensity score matching (PSM).
Results Following PSM, each analysis was conducted on cohorts via the matching of 70:140 (TAF:TDF), 89:89 (TAF:inactive CHB), 140:560 (TAF:non-HBV infected control), and 368:1,472 (TDF:non-HBV-infected control). A significant decrease in the total cholesterol (TC) level was noted at 48 weeks in the TDF group compared to the TAF group (176.3±32.9 vs. 156.7±27.7, P<0.001) and the non-HBV-infected control group (175.0±29.5 vs. 156.2±28.3, P<0.001). However, no significant change in TC was observed in the TAF group and inactive CHB or non-HBV-infected control groups at 48 weeks. For the subgroup analyses of TAF vs. non-HBV-infected control subjects and inactive CHB patients whose detailed lipid profile information were available, no between-group differences in TC, low-density lipoprotein (LDL)-cholesterol, highdensity lipoprotein (HDL)-cholesterol, TC/HDL ratio, and LDL/HDL ratio were observed at 48 weeks.
Conclusions TDF seems to have a lipid-lowering effect compared to the non-HBV-infected control and TAF-treated groups. However, in real practice, TAF might not worsen the lipid profiles of subjects compared to non-HBV-infected controls and patients with inactive CHB.
Citations
Citations to this article as recorded by
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti Alimentary Pharmacology & Therapeutics.2026; 63(1): 132. CrossRef
Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis Xinxin Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan Journal of Viral Hepatitis.2025;[Epub] CrossRef
Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim Journal of Medical Virology.2025;[Epub] CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim Hepatology International.2025; 19(4): 959. CrossRef
Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real‐World Cohort Erdem Bektas, Aysenur Yilmaz, Cevat Ilteris Kikili, Kanan Nuriyev, Zulal Istemihan, Ibrahim Volkan Senkal, Ziya Imanov, Bilger Cavus, Asli Cifcibasi Ormeci, Filiz Akyuz, Kadir Demir, Selman Fatih Besisik, Sabahattin Kaymakoglu, Sreeja Dattachoudhury International Journal of Hepatology.2025;[Epub] CrossRef
Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis Ping‐Yu Hsu, Hui‐Chen Su, Mi‐Chia Ma, Chien‐An Chen, Sin‐Yi Yu, Yi‐Ming Hua Journal of Medical Virology.2025;[Epub] CrossRef
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun, Tyng-Yuan Jang PLOS One.2025; 20(5): e0324897. CrossRef
Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients Erdem Bektas, Aysenur Yilmaz, Cevat Ilteris Kikili, Kanan Nuriyev, Zulal Istemihan, Ibrahim Volkan Senkal, Ziya Imanov, Bilger Cavus, Asli Cifcibasi Ormeci, Filiz Akyuz, Kadir Demir, Selman Fatih Besisik, Sabahattin Kaymakoglu Transplant Infectious Disease.2025;[Epub] CrossRef
Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis Yuan-Hai Zhou, Nan Cai, Yu-Xin Chen, Yong-Lu Su, Peng Hu Frontiers in Pharmacology.2025;[Epub] CrossRef
Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim Journal of Medical Virology.2025;[Epub] CrossRef
Evaluation of tenofovir alafenamide– versus tenofovir disoproxil fumarate–containing regimens on renal outcomes: systematic literature review and meta-analysis Xi Liang, Kyu Yun Park, Haeseon Lee, Haopeng Liu, Connor Willis, Tara Dhippayom, Rachel Rogers, Amy R. Weinberg, Julia Green, Aileen Chi, Nathorn Chaiyakunapruk BMC Nephrology.2025;[Epub] CrossRef
Current Clinical Applications of Entecavir in Hepatitis B Viruses Infection Cigdem Mermutluoglu, Halim Bayram, Tugce Simsek, Abdullah Golbol, Evrim Kuscu, Hande Cam, Yusuf Arslan, Rukkiye Bulut, Hakan Celik, Mustafa Celen International Journal of Infectious Diseases and Therapy.2025; 10(4): 68. CrossRef
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B Pin‐Nan Cheng, I‐Cher Feng, Jyh‐Jou Chen, Hsing‐Tao Kuo, Pei‐Lun Lee, Ming‐Lung Yu, Yen‐Cheng Chiu, Hung‐Chih Chiu, Shih‐Chieh Chien, Pei‐Jer Chen, Chun‐Jen Liu Alimentary Pharmacology & Therapeutics.2024; 59(2): 230. CrossRef
Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B Shuhei Hige, Kouji Aoki, Daisuke Nakamoto, John F. Flaherty, Irina Botros, Hajime Mizutani, Akinobu Ishizaki, Hiroki Konishi, Jason Yuan, Masahisa Jinushi, Leslie J. Ng Journal of Viral Hepatitis.2024; 31(4): 165. CrossRef
Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis Kexin Tong, Mingjing Chen, Danni Wang, Haifeng Dai, Jiayi Peng, Jia Zhang, Jiao Zhou, Yujiao Chang, Wenxiang Huang European Journal of Clinical Pharmacology.2024; 80(3): 335. CrossRef
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide” Pin-Nan Cheng, Ming-Lung Yu Clinical and Molecular Hepatology.2024; 30(4): 1031. CrossRef
Application of Tenofovir Alafenamide Fumarate in Patients with Chronic Hepatitis B 雪 刘 Advances in Clinical Medicine.2024; 14(02): 3550. CrossRef
The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang Heliyon.2024; 10(7): e28653. CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer Pin-Nan Cheng, Ming-Lung Yu Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply Hyeyeon Hong, Jonggi Choi Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef
Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye Frontiers in Medicine.2024;[Epub] CrossRef
Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-naïve chronic hepatitis B patients: a network meta-analysis Jaejun Lee, Ahlim Lee, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hyun Yang The Korean Journal of Internal Medicine.2024; 39(4): 577. CrossRef
Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B Hyunjae Shin, Gyung Sun Lim, Jae Woong Yoon, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yuri Cho, Yun Bin Lee, Eun Ju Cho, Bo Hyun Kim, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim Journal of Medical Virology.2024;[Epub] CrossRef
Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu Virology Journal.2024;[Epub] CrossRef
Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis Jeong‐Ju Yoo, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Min Jae Kim Journal of the International AIDS Society.2024;[Epub] CrossRef
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao Scientific Reports.2024;[Epub] CrossRef
Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment Jiezuan Yang, Haifeng Lu, Baikun Chen, Lili Jiang, Hua Zhang, Ping Ye, Linfeng Jin, Lele Zhu Journal of Immunology Research.2023; 2023: 1. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao Heliyon.2023; 9(1): e13113. CrossRef
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial Jonggi Choi, Young-Suk Lim, Ji-Hoon Kim, Kwan Soo Byun, Byung Chul Yoo Clinical Gastroenterology and Hepatology.2023; 21(12): 3185. CrossRef
Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Hepatology International.2023; 17(4): 860. CrossRef
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang BMC Cancer.2023;[Epub] CrossRef
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs? Jonggi Choi, Won-Mook Choi, Young-Suk Lim Clinics in Liver Disease.2023; 27(4): 809. CrossRef
Comparisons of Insulin Resistance- and Steatosis-Based Scores in Monitoring Metabolic Associated Fatty Liver Disease Treatment Response Junzhao Ye, Yansong Lin, Congxian Shao, Yanhong Sun, Shiting Feng, Bihui Zhong Annals of Nutrition and Metabolism.2023; 79(5): 448. CrossRef
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi Clinical and Molecular Hepatology.2023; 30(1): 49. CrossRef
Incidence of Side Effects During Tenofovir Alafenamide Monotherapy in Patients with Chronic Hepatitis B Fada Wang, Jing Zhou, Lanqing Li, Yujing Li, Yongfang Liu, Enqiang Chen Diseases and Research.2023; 3(1): 11. CrossRef
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles Hung-Yao Lin, Tai-Chung Tseng Clinical and Molecular Hepatology.2022; 28(2): 181. CrossRef
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B Meng‐Lan Wang, En‐Qiang Chen Alimentary Pharmacology & Therapeutics.2022; 56(6): 1090. CrossRef
Background/Aims Low-level viremia (LLV) after nucleos(t)ide analog treatment was presented as a possible cause of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). However, detailed information on patients’ adherence in the real world was lacking. This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment.
Methods We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of <2,000 IU/mL detectable hepatitis B virus DNA during the follow-up period. Good adherence to medication was defined as a cumulative adherence ≥90% per study period.
Results Without considering adherence in the entire cohort (n=894), multivariate analysis of the HCC incidence showed that LLV was an independent prognostic factor in addition to other traditional risk factors in the entire cohort (P=0.031). Good adherence group comprised 617 patients (69.0%). No significant difference was found between maintained virologic response and LLV groups in terms of the incidence of liver-related death or transplantation, HCC, and hepatic decompensation in good adherence group, according to multivariate analyses.
Conclusions In patients with treatment-naïve CHB and good adherence to ETV treatment in the real world, LLV during treatment is not a predictive factor for HCC and cirrhotic complications. It may be unnecessary to adjust their antiviral agent for patients with good adherence who experience LLV during ETV treatment.
Citations
Citations to this article as recorded by
Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B Jianna Zhang, Zhiqiang Lan, Kailu Zhu, Sijie Yu, Shibo Li, Yu Huang BMC Cancer.2025;[Epub] CrossRef
Serum hepatitis B virus RNA in low-level viremia of chronic hepatitis B: clinical features and association with virological response Yongbin Wu, Guifang Tang, Jian Wen, Ying Wan, Yufei Wang, Ling Li Virology Journal.2025;[Epub] CrossRef
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo Journal of Hepatology.2025; 83(2): 502. CrossRef
Prevalence of low-level viremia in the treatment of chronic hepatitis B in China: a systematic review and meta-analysis Lu Xie, Guangwei Liu, Yanan Liu, Pengyu Li, Huijun Guo BMJ Open.2025; 15(6): e088756. CrossRef
Specific association and independent predictive value of HBV RNA in the disease progression of hepatitis B with low-level viremia Liang Xu, Bin Yin, Dandan Chen, Xia Xiong, Yongfeng Yang, Xuping Wu Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102648. CrossRef
Adding pegylated interferon-α to nucleos(t)ide analogs improves HBsAg clearance in chronic hepatitis B with low-level viremia Lilin Wang, Junfeng Lu, Dan Liu, Shan Ren, Xinyue Chen, Zhongjie Hu, Sujun Zheng Frontiers in Medicine.2025;[Epub] CrossRef
Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim Scientific Reports.2025;[Epub] CrossRef
Predictors of low-level viremia in chronic hepatitis B and the efficacy of pegylated interferon-alpha: a real-world study Wenyuan Zhang, Jia Chen, Wenjin Sun, Nana Xie, Fangbing Tian, Wencong Zhang, Qiurong Ruan, Jianxin Song Virology Journal.2025;[Epub] CrossRef
Elevated hepatitis B virus RNA levels in HBeAg‐positive patients with low‐level viraemia or previous low‐level viraemia Tao Li, Yan Chen, Yushuang Zhang, Shuo Wu, Lixin Zhang, Lei Wang Journal of Viral Hepatitis.2024; 31(8): 504. CrossRef
Management of antiviral treatment for chronic hepatitis B patients with high viral load Ken Lin, Su-Wen Jiang, Ai-Rong Hu World Chinese Journal of Digestology.2024; 32(9): 625. CrossRef
Long-term clinical outcomes of maintenance therapy with nucleos(t)ide analogues in chronic hepatitis B patients with low-level viremia: A systematic review and meta-analysis He-Min Chen, Ming Xia, Xu-Feng Zheng, Ji-Cai Zheng World Chinese Journal of Digestology.2024; 32(9): 686. CrossRef
Multiple Low‐Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy Zhengzhao Lu, Ya‐Meng Sun, Shuyan Chen, Tongtong Meng, Bingqiong Wang, Jialing Zhou, Xiaoning Wu, Xinyan Zhao, Xiaojuan Ou, Yuan‐Yuan Kong, Jidong Jia, Xinyu Zhao, Hong You Journal of Viral Hepatitis.2024; 31(12): 898. CrossRef
Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients Wei-Chun Lin, Ke Lin, Ming-Kai Li, Xiao Liu, Yi-Fei Huang, Xing Wang, Bin Wu World Journal of Hepatology.2024; 16(11): 1321. CrossRef
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi, Hepatology.2023; 77(5): 1746. CrossRef
The urgency to expand the antiviral indications of general chronic hepatitis B patients Ping Fan, Lan-Qing Li, En-Qiang Chen Frontiers in Medicine.2023;[Epub] CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim Alimentary Pharmacology & Therapeutics.2023; 58(1): 99. CrossRef
Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim Journal of Korean Medical Science.2023;[Epub] CrossRef
Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B Shun Ishido, Nobuharu Tamaki, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Yuka Takahashi, Kaoru Tsuchiya, H JGH Open.2023; 7(8): 567. CrossRef
Clinical Research on LLV Patients with Chronic Hepatitis B 琳 杨 Advances in Clinical Medicine.2023; 13(08): 13038. CrossRef
Patient Preferences and Their Influence on Chronic Hepatitis B-A Review Lin Zhang, Yunyue Liu, Jinping Tian Patient Preference and Adherence.2023; Volume 17: 3119. CrossRef
Research Progress of Low-Level Viraemia in Patients with Chronic Hepatitis B 祥运 张 Advances in Clinical Medicine.2023; 13(12): 20083. CrossRef
Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim American Journal of Gastroenterology.2022; 117(2): 288. CrossRef
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2022; 14(3): 711. CrossRef
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee Clinical and Molecular Hepatology.2022; 28(3): 351. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim Cancers.2021; 13(14): 3424. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren Chinese Medical Journal.2021; 134(23): 2810. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2021; 13(23): 5892. CrossRef
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Hepatology International.2021; 15(5): 1083. CrossRef
How does low-level viremia affect the prognosis of patients with chronic hepatitis B? Hye Won Lee, Beom Kyung Kim Clinical and Molecular Hepatology.2020; 26(3): 376. CrossRef
Background/Aims Tenofovir disoproxil fumarate (TDF) monotherapy for 48 weeks provided a virological response comparable to that of TDF and entecavir (ETV) combination therapy in patients infected with ETV-resistant hepatitis B virus (HBV). Little long-term data in routine clinical practice are available regarding the optimal treatment of patients with ETV-resistant HBV.
Methods We investigated the long-term antiviral efficacy of combination therapy of TDF+lamivudine (LAM) or TDF+ETV compared to that of TDF monotherapy in 73 patients with resistance to both LAM and ETV.
Results Patients were treated with TDF monotherapy (n=12), TDF+LAM (n=19), or TDF+ETV (n=42) for more than 6 months. The median duration of TDF-based rescue therapy was 37 months. Virologic response (VR) was found in 63 patients (86.3%). The rates of VR among the three groups (TDF monotherapy, TDF+LAM, and TDF+ETV) were not statistically different (log-rank P=0.200) at 12 months (59.3%, 78.9%, and 51.8%, respectively) or at 24 months (88.4%, 94.7%, and 84.2%). In addition, treatment efficacy of TDF-based combination or TDF monotherapy was not statistically different with ETV-resistant strains or exposure to other antiviral agents. In multivariate analysis, only lower baseline HBV DNA level was an independent predictor for VR (hazard ratio, 0.723; 95% confidence interval, 0.627-0.834; P<0.001).
Conclusions TDF monotherapy was as effective as combination therapy of TDF+LAM or TDF+ETV in maintaining long-term viral suppression in chronic hepatitis B patients with resistance to both LAM and ETV. HBV DNA level at the start of TDF rescue therapy was the only independent predictor of subsequent VR.
Citations
Citations to this article as recorded by
Efficacy and Safety of Tenofovir Plus Entecavir Combination Therapy Versus Tenofovir Monotherapy in Chronic Hepatitis B Virus Patients With Resistance or Partial Response to Entecavir: A Systematic Review and Meta-analysis Syed H. Ali, Muhammad H. Shah, Sakshi Roy, Hareesha R. Bharadwaj, Joecelyn K. Tan, Medha S. Rao, Muhtasim Fuad, Arjun Ahluwalia, Aditya Gaur, Priyal Dalal, Arkadeep Dhali, Harishankar Gopakumar Journal of Clinical and Experimental Hepatology.2025; 15(4): 102541. CrossRef
Tenofovir-Associated Kidney Dysfunction and Bone Fracture: A Case Report and Literature Review KK Athish, Shobhana Nayak Rao, Venkat H Marimuthu, Vamsi Krishna, Anwadevi Arun Cureus.2024;[Epub] CrossRef
Bilateral atraumatic neck of femur fractures secondary to tenofovir-induced fanconi syndrome Vikaesh Moorthy, Kelvin Guoping Tan Journal of Orthopaedic Reports.2023; 2(1): 100123. CrossRef
Molecular characterization of hepatitis B virus (HBV) isolated from a pediatric case of acute lymphoid leukemia, with a delayed response to antiviral treatment: a case report Chien-Yu Chen, Christina Hajinicolaou, Priya Walabh, Luicer Anne Olubayo Ingasia, Ernest Song, Anna Kramvis BMC Pediatrics.2022;[Epub] CrossRef
Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis Xuefeng Ma, Shousheng Liu, Mengke Wang, Yifen Wang, Shuixian Du, Yongning Xin, Shiying Xuan Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef
Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B F. Higuera-de-la-Tijera, G.E. Castro-Narro, J.A. Velarde-Ruiz Velasco, E. Cerda-Reyes, R. Moreno-Alcántar, I. Aiza-Haddad, M. Castillo-Barradas, L.E. Cisneros-Garza, M. Dehesa-Violante, J. Flores-Calderón, M.S. González-Huezo, E. Márquez-Guillén, L.E. Muñ Revista de Gastroenterología de México (English Edition).2021; 86(4): 403. CrossRef
Asociación Mexicana de Hepatología A.C. Guía Clínica de Hepatitis B F. Higuera-de-la-Tijera, G.E. Castro-Narro, J.A. Velarde-Ruiz Velasco, E. Cerda-Reyes, R. Moreno-Alcántar, I. Aiza-Haddad, M. Castillo-Barradas, L.E. Cisneros-Garza, M. Dehesa-Violante, J. Flores-Calderón, M.S. González-Huezo, E. Márquez-Guillén, L.E. Muñ Revista de Gastroenterología de México.2021; 86(4): 403. CrossRef
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn Clinical and Molecular Hepatology.2020; 26(3): 352. CrossRef
Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study Hyung Joon Yim, Sang Jun Suh, Young Kul Jung, Seong Gyu Hwang, Yeon Seok Seo, Soon Ho Um, Sae Hwan Lee, Young Seok Kim, Jae Young Jang, In Hee Kim, Hyoung Su Kim, Ji Hoon Kim, Young Sun Lee, Eileen L. Yoon, Myeong Jun Song, Jun Yong Park Journal of Viral Hepatitis.2020; 27(12): 1306. CrossRef
Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis Si-Si Yang, Cheng-Wei Cai, Xue-Qing Ma, Jia Xu, Cheng-Bo Yu Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 507. CrossRef
Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection Hye Won Lee, Jun Yong Park, Jin Woo Lee, Ki Tae Yoon, Chang Wook Kim, Hana Park, Young Seok Kim, Soon Ku Paik, Jung Il Lee, Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn Clinical Gastroenterology and Hepatology.2019; 17(7): 1348. CrossRef
Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate Dohyeong Lee, Byung Cheol Yun, Kwang Il Seo, Byung Hoon Han, Sang Uk Lee, Eun Taek Park, Jin Wook Lee, Joonho Jeong Medicine.2019; 98(50): e18351. CrossRef
Effect of tenofovir on renal function in patients with chronic hepatitis B Woo Jin Jung, Jae Young Jang, Won Young Park, Soung Won Jeong, Hee Jeong Lee, Sang Joon Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Suyeon Park, Baigal Baymbajav Medicine.2018; 97(7): e9756. CrossRef
Long-term Outcomes in Patients with HBV Treated with Antiviral Agents Mauro Viganò, Alessandro Loglio, Pietro Lampertico Current Hepatology Reports.2018; 17(4): 502. CrossRef
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? Yun Bin Lee, Jeong-Hoon Lee Clinical and Molecular Hepatology.2017; 23(3): 219. CrossRef
Background/Aims Tenofovir disoproxil fumarate (TDF) exhibits similar antiviral efficacy against treatment-naïve and lamivudine (LAM)-resistant chronic hepatitis B (CHB). However, there are few clinical reports on the antiviral effects of TDF–LAM combination therapy compared to TDF monotherapy in patients with LAM-resistant CHB.
Methods We investigated the antiviral efficacy of TDF monotherapy vs. TDF–LAM combination therapy in 103 patients with LAM-resistant CHB.
Results The study subjects were treated with TDF alone (n=40) or TDF–LAM combination therapy (n=63) for ≥6 months. The patients had previously been treated with TDF-based rescue therapy for a median of 30.0 months (range, 8–36 months). A virologic response (VR) was achieved in 99 patients (96.1%): 95.0% (38/40) of patients in the TDF monotherapy group and 96.8% (61/63) of patients in the TDF–LAM combination therapy group. The VR rates were not significantly different between the TDF monotherapy and TDF–LAM combination therapy groups (88.9 vs. 87.3% at month 12, and 94.4 vs. 93.7% at month 24, log-rank P=0.652). Univariate and multivariate analyses revealed that none of the pretreatment factors were significantly associated with VR.
Conclusions TDF monotherapy was as effective as TDF–LAM combination therapy for maintaining viral suppression in the vast majority of patients with LAM-resistant CHB, which suggests that TDF add-on therapy with LAM is unnecessary.
Citations
Citations to this article as recorded by
Research Status of Antiviral Therapy for Chronic Hepatitis B 漫 赵 Advances in Clinical Medicine.2025; 15(04): 1194. CrossRef
First
Prev
